344 related articles for article (PubMed ID: 20008221)
1. The role of NOTCH1 signaling in T-ALL.
Ferrando AA
Hematology Am Soc Hematol Educ Program; 2009; ():353-61. PubMed ID: 20008221
[TBL] [Abstract][Full Text] [Related]
2. Recent advances on NOTCH signaling in T-ALL.
Tzoneva G; Ferrando AA
Curr Top Microbiol Immunol; 2012; 360():163-82. PubMed ID: 22673746
[TBL] [Abstract][Full Text] [Related]
3. Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia.
Real PJ; Tosello V; Palomero T; Castillo M; Hernando E; de Stanchina E; Sulis ML; Barnes K; Sawai C; Homminga I; Meijerink J; Aifantis I; Basso G; Cordon-Cardo C; Ai W; Ferrando A
Nat Med; 2009 Jan; 15(1):50-8. PubMed ID: 19098907
[TBL] [Abstract][Full Text] [Related]
4. NOTCH inhibition and glucocorticoid therapy in T-cell acute lymphoblastic leukemia.
Real PJ; Ferrando AA
Leukemia; 2009 Aug; 23(8):1374-7. PubMed ID: 19357700
[TBL] [Abstract][Full Text] [Related]
5. Therapeutic targeting of NOTCH1 signaling in T-cell acute lymphoblastic leukemia.
Palomero T; Ferrando A
Clin Lymphoma Myeloma; 2009; 9 Suppl 3(Suppl 3):S205-10. PubMed ID: 19778842
[TBL] [Abstract][Full Text] [Related]
6. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
Larson Gedman A; Chen Q; Kugel Desmoulin S; Ge Y; LaFiura K; Haska CL; Cherian C; Devidas M; Linda SB; Taub JW; Matherly LH
Leukemia; 2009 Aug; 23(8):1417-25. PubMed ID: 19340001
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antileukemic therapies in
Sanchez-Martin M; Ambesi-Impiombato A; Qin Y; Herranz D; Bansal M; Girardi T; Paietta E; Tallman MS; Rowe JM; De Keersmaecker K; Califano A; Ferrando AA
Proc Natl Acad Sci U S A; 2017 Feb; 114(8):2006-2011. PubMed ID: 28174276
[TBL] [Abstract][Full Text] [Related]
8. In vitro validation of gamma-secretase inhibitors alone or in combination with other anti-cancer drugs for the treatment of T-cell acute lymphoblastic leukemia.
De Keersmaecker K; Lahortiga I; Mentens N; Folens C; Van Neste L; Bekaert S; Vandenberghe P; Odero MD; Marynen P; Cools J
Haematologica; 2008 Apr; 93(4):533-42. PubMed ID: 18322257
[TBL] [Abstract][Full Text] [Related]
9. T cell acute lymphoblastic leukemia/lymphoma: a human cancer commonly associated with aberrant NOTCH1 signaling.
Pear WS; Aster JC
Curr Opin Hematol; 2004 Nov; 11(6):426-33. PubMed ID: 15548998
[TBL] [Abstract][Full Text] [Related]
10. More Insights on the Use of γ-Secretase Inhibitors in Cancer Treatment.
López-Nieva P; González-Sánchez L; Cobos-Fernández MÁ; Córdoba R; Santos J; Fernández-Piqueras J
Oncologist; 2021 Feb; 26(2):e298-e305. PubMed ID: 33191568
[TBL] [Abstract][Full Text] [Related]
11. The Notch driven long non-coding RNA repertoire in T-cell acute lymphoblastic leukemia.
Durinck K; Wallaert A; Van de Walle I; Van Loocke W; Volders PJ; Vanhauwaert S; Geerdens E; Benoit Y; Van Roy N; Poppe B; Soulier J; Cools J; Mestdagh P; Vandesompele J; Rondou P; Van Vlierberghe P; Taghon T; Speleman F
Haematologica; 2014 Dec; 99(12):1808-16. PubMed ID: 25344525
[TBL] [Abstract][Full Text] [Related]
12. Molecular pathogenesis and targeted therapies for NOTCH1-induced T-cell acute lymphoblastic leukemia.
Paganin M; Ferrando A
Blood Rev; 2011 Mar; 25(2):83-90. PubMed ID: 20965628
[TBL] [Abstract][Full Text] [Related]
13. Notch1 gene mutations target KRAS G12D-expressing CD8+ cells and contribute to their leukemogenic transformation.
Kong G; Du J; Liu Y; Meline B; Chang YI; Ranheim EA; Wang J; Zhang J
J Biol Chem; 2013 Jun; 288(25):18219-27. PubMed ID: 23673656
[TBL] [Abstract][Full Text] [Related]
14. NOTCH1-induced T-cell leukemia in transgenic zebrafish.
Chen J; Jette C; Kanki JP; Aster JC; Look AT; Griffin JD
Leukemia; 2007 Mar; 21(3):462-71. PubMed ID: 17252014
[TBL] [Abstract][Full Text] [Related]
15. The relevance of PTEN-AKT in relation to NOTCH1-directed treatment strategies in T-cell acute lymphoblastic leukemia.
Mendes RD; Canté-Barrett K; Pieters R; Meijerink JP
Haematologica; 2016 Sep; 101(9):1010-7. PubMed ID: 27582570
[TBL] [Abstract][Full Text] [Related]
16. PI3Kγ/δ and NOTCH1 Cross-Regulate Pathways That Define the T-cell Acute Lymphoblastic Leukemia Disease Signature.
Efimenko E; Davé UP; Lebedeva IV; Shen Y; Sanchez-Quintero MJ; Diolaiti D; Kung A; Lannutti BJ; Chen J; Realubit R; Niatsetskaya Z; Ten V; Karan C; Chen X; Califano A; Diacovo TG
Mol Cancer Ther; 2017 Oct; 16(10):2069-2082. PubMed ID: 28716817
[TBL] [Abstract][Full Text] [Related]
17. New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.
Hales EC; Taub JW; Matherly LH
Cell Signal; 2014 Jan; 26(1):149-61. PubMed ID: 24140475
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells.
Rao SS; O'Neil J; Liberator CD; Hardwick JS; Dai X; Zhang T; Tyminski E; Yuan J; Kohl NE; Richon VM; Van der Ploeg LH; Carroll PM; Draetta GF; Look AT; Strack PR; Winter CG
Cancer Res; 2009 Apr; 69(7):3060-8. PubMed ID: 19318552
[TBL] [Abstract][Full Text] [Related]
19. Targeting the Notch1 and mTOR pathways in a mouse T-ALL model.
Cullion K; Draheim KM; Hermance N; Tammam J; Sharma VM; Ware C; Nikov G; Krishnamoorthy V; Majumder PK; Kelliher MA
Blood; 2009 Jun; 113(24):6172-81. PubMed ID: 19246562
[TBL] [Abstract][Full Text] [Related]
20. High selective pressure for Notch1 mutations that induce Myc in T-cell acute lymphoblastic leukemia.
Chiang MY; Wang Q; Gormley AC; Stein SJ; Xu L; Shestova O; Aster JC; Pear WS
Blood; 2016 Nov; 128(18):2229-2240. PubMed ID: 27670423
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
